Key Insights

Highlights

Success Rate

96% trial completion (above average)

Published Results

15 trials with published results (14%)

Research Maturity

69 completed trials (63% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

2.8%

3 terminated out of 109 trials

Success Rate

95.8%

+9.3% vs benchmark

Late-Stage Pipeline

19%

21 trials in Phase 3/4

Results Transparency

22%

15 of 69 completed with results

Key Signals

15 with results96% success

Data Visualizations

Phase Distribution

81Total
Not Applicable (28)
Early P 1 (1)
P 1 (10)
P 2 (21)
P 3 (11)
P 4 (10)

Trial Status

Completed69
Unknown17
Recruiting6
Withdrawn5
Terminated3
Active Not Recruiting3

Trial Success Rate

95.8%

Benchmark: 86.5%

Based on 69 completed trials

Clinical Trials (109)

Showing 20 of 20 trials
NCT07055542Not ApplicableRecruitingPrimary

Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study

NCT04699604Phase 3RecruitingPrimary

A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)

NCT06960382Phase 1Recruiting

Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Asthma

NCT07425639Recruiting

ROLL'YN-OMA: an Observational Study in Patients Treated by Omlyclo®, an Omalizumab Biosimilar

NCT05186025Active Not Recruiting

Tyrosine Allergoid Paediatric and Adult Study

NCT07352488Not ApplicableNot Yet RecruitingPrimary

Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome

NCT07342803Phase 2RecruitingPrimary

Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients

NCT05008965Phase 2RecruitingPrimary

Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma

NCT06592768Phase 1TerminatedPrimary

A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma

NCT05191186Phase 3Completed

Documentation of Efficacy of Intralymphatic Allergen Immunotherapy

NCT02767973Not ApplicableSuspended

To Identify Persons Who Are Susceptible to WSP-induced Inflammation and Examine the Role of GSTM1 and Other Factors in This Susceptibility

NCT07114133Not ApplicableEnrolling By Invitation

A Study on the Efficacy of Environmental Probiotics in Patients With Cat Hair Allergies

NCT01536522Early Phase 1Enrolling By Invitation

Asthma Inflammation Research

NCT05297760Phase 1Completed

Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract

NCT06438757Phase 2Active Not RecruitingPrimary

Trial of JYB1904 in Patients With Allergic Asthma

NCT06486662Phase 1CompletedPrimary

A Clinical Study Investigating OM-85-IN Safety and Tolerability in Healthy Volunteers and Mild Allergic Asthma Patients

NCT06771934Active Not RecruitingPrimary

Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma

NCT06267261Not ApplicableCompletedPrimary

Efficacy of Face Mask in Reducing Respiratory Allergic Symptoms in Birch-allergic Subjects in ALYATEC Exposure Chamber

NCT06494345Phase 1CompletedPrimary

A Study of Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy Volunteers

NCT03861910Completed

Dietary Choice for the Management of Cow's Milk Allergy Influences Other Allergic Manifestations

Scroll to load more

Research Network

Activity Timeline